MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.
Julie LecuelleLaure FavierCléa FraisseAurélie LagrangeCoureche KaderbhaiRomain BoidotSandy ChevrierPhilippe JoubertBertrand RoutyCaroline TruntzerFrançois GhiringhelliPublished in: Journal for immunotherapy of cancer (2022)
MER4 ERV expression is useful to stratify risk and predict PFS and OS in patients treated with ICI for NSCLC. It also improves the predictive power of other known transcriptomic signatures.